Passage Bio, Inc.
PASG
$4.59
$0.020.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.74% | 13.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.12% | 19.47% | |||
| Operating Income | 14.12% | -19.47% | |||
| Income Before Tax | 41.78% | -67.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 41.78% | -67.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 41.78% | -67.54% | |||
| EBIT | 14.12% | -19.47% | |||
| EBITDA | 13.89% | -19.93% | |||
| EPS Basic | 42.25% | -67.49% | |||
| Normalized Basic EPS | 14.25% | -22.24% | |||
| EPS Diluted | 42.25% | -67.49% | |||
| Normalized Diluted EPS | 14.25% | -22.24% | |||
| Average Basic Shares Outstanding | 0.82% | 0.03% | |||
| Average Diluted Shares Outstanding | 0.82% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||